Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Invested Capital (2019 - 2023)

Alx Oncology Holdings' Invested Capital history spans 5 years, with the latest figure at $168.8 million for Q3 2023.

  • For Q3 2023, Invested Capital fell 41.75% year-over-year to $168.8 million; the TTM value through Sep 2023 reached $168.8 million, down 41.75%, while the annual FY2022 figure was $265.1 million, 27.3% down from the prior year.
  • Invested Capital for Q3 2023 was $168.8 million at Alx Oncology Holdings, down from $212.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $429.8 million in Q4 2020 and bottomed at -$78.4 million in Q2 2020.
  • The 5-year median for Invested Capital is $261.6 million (2020), against an average of $209.1 million.
  • The largest annual shift saw Invested Capital surged 708.51% in 2020 before it tumbled 41.75% in 2023.
  • A 5-year view of Invested Capital shows it stood at -$70.6 million in 2019, then soared by 708.51% to $429.8 million in 2020, then decreased by 15.16% to $364.7 million in 2021, then decreased by 27.3% to $265.1 million in 2022, then tumbled by 36.35% to $168.8 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Invested Capital are $168.8 million (Q3 2023), $212.7 million (Q2 2023), and $251.0 million (Q1 2023).